阿奇霉素与环丙沙星体外抑制人鼻窦上皮IL-8分泌且不破坏上皮完整性
本研究评估阿奇霉素和/或环丙沙星在CASS释放可达浓度下对铜绿假单胞菌LPS刺激的原代人鼻窦上皮细胞(HSNECs)的影响。结果显示阿奇霉素在所有测试浓度下均显著降低IL-8分泌,联合环丙沙星亦显著降低IL-8,且未损害上皮完整性(TEER、旁细胞通透性、LDH)和纤毛摆动频率。
要点
- 阿奇霉素在6、60、180 μg/mL浓度下均显著减少LPS刺激的HSNECs分泌IL-8。
- 阿奇霉素6 μg/mL联合环丙沙星2.4 μg/mL显著降低IL-8,优于单用LPS组。
- 药物未负影响TEER、旁细胞通透性、LDH释放或CBF,提示细胞完整性和功能保留。
核心结论
- 阿奇霉素在CASS持续释放可达浓度下降低铜绿假单胞菌LPS诱导的HSNECs IL-8产生。
研究设计与样本
- 体外研究:用铜绿假单胞菌LPS刺激原代人鼻窦上皮细胞(HSNECs),给予阿奇霉素和/或环丙沙星处理。
主要发现
- 阿奇霉素所有测试浓度均显著降低IL-8分泌:对照5.77±0.39 ng/mL,6 μg/mL组4.58±0.40 ng/mL,60 μg/mL组4.31±0.06 ng/mL,180 μg/mL组4.27±0.26 ng/mL,p<0.05。
- 阿奇霉素6 μg/mL联合环丙沙星2.4 μg/mL显著降低IL-8:联合组4.61±0.29 ng/mL vs LPS组7.35±0.89 ng/mL,p<0.01。
- 药物未负影响TEER、旁细胞通透性、LDH释放或CBF。
关键数值与推荐
- 阿奇霉素测试浓度:6、60、180 μg/mL;环丙沙星测试浓度:2.4 μg/mL。
- IL-8分泌用ELISA定量;上皮完整性用TEER、FITC-右旋糖酐旁细胞通透性、LDH assay评估;功能用CBF评估。
临床怎么用
- CASS除抗菌外可能通过抗炎作用(降低IL-8)为顽固性慢性鼻窦炎(CRS)患者提供额外获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We recently developed a ciprofloxacin and azithromycin sinus stent (CASS) to target recalcitrant infections in chronic rhinosinusitis (CRS). The objective of this study was to evaluate the anti-inflammatory activity of azithromycin released from the CASS and assess the impact on the integrity and function of primary human sinonasal epithelial cells (HSNECs). METHODS: Pseudomonas aeruginosa lipopolysaccharide (LPS)-stimulated HSNECs were treated with azithromycin and/or ciprofloxacin at concentrations attainable from CASS release. Interleukin-8 (IL-8) secretion was quantified by enzyme-linked immunosorbent assay (ELISA). Epithelial integrity (transepithelial resistance [TEER], paracellular permeability [fluorescein isothiocyanate-labeled dextran], lactate dehydrogenase [LDH] assays) and function (ciliary beat frequency [CBF]) were also evaluated. RESULTS: Azithromycin significantly reduced secreted IL-8 from P. aeruginosa LPS-stimulated HSNECs at all concentrations tested (mean ± standard deviation; control = 5.77 ± 0.39 ng/mL, azithromycin [6 μg/mL] = 4.58 ± 0.40 ng/mL, azithromycin [60 µg/mL] = 4.31 ± 0.06, azithromycin [180 µg/mL] = 4.27 ± 0.26 ng/mL, p < 0.05). Co-incubation with azithromycin (6 µg/mL) and ciprofloxacin (2.4 µg/mL) in LPS-stimulated HSNECs also displayed a significant reduction in secreted IL-8 when compared to P. aeruginosa LPS alone (co-treatment = 4.61 ± 0.29 ng/mL, P. aeruginosa LPS = 7.35 ± 0.89 ng/mL, p < 0.01). The drugs did not negatively impact TEER, paracellular permeability, LDH release, or CBF, indicating retention of cell integrity and function. CONCLUSION: Azithromycin decreased P. aeruginosa LPS IL-8 production in HSNECs at drug concentrations attainable with sustained release of azithromycin from the CASS. In addition to antibacterial activity, anti-inflammatory properties of the CASS should provide further benefit for patients with recalcitrant CRS.
引用
- Lim DJ, Thompson HM, Walz CR, et al. Azithromycin and ciprofloxacin inhibit interleukin-8 secretion without disrupting human sinonasal epithelial integrity in vitro. Int Forum Allergy Rhinol. 2020. PMID: 32725797. doi:10.1002/alr.22656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。